Last reviewed 2026-04-19 · How we verify

SYL18001 sodium Middle dose q.d

Sylentis, S.A. · Phase 1 active Small molecule

SYL18001 sodium Middle dose q.d is a Small molecule drug developed by Sylentis, S.A.. It is currently in Phase 1 development.

At a glance

Generic name	SYL18001 sodium Middle dose q.d
Sponsor	Sylentis, S.A.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SYL18001 sodium Middle dose q.d CI brief — competitive landscape report
SYL18001 sodium Middle dose q.d updates RSS · CI watch RSS
Sylentis, S.A. portfolio CI

Frequently asked questions about SYL18001 sodium Middle dose q.d

What is SYL18001 sodium Middle dose q.d?

SYL18001 sodium Middle dose q.d is a Small molecule drug developed by Sylentis, S.A..

Who makes SYL18001 sodium Middle dose q.d?

SYL18001 sodium Middle dose q.d is developed by Sylentis, S.A. (see full Sylentis, S.A. pipeline at /company/sylentis-s-a).

What development phase is SYL18001 sodium Middle dose q.d in?

SYL18001 sodium Middle dose q.d is in Phase 1.

Manufacturer: Sylentis, S.A. — full pipeline
Compare: SYL18001 sodium Middle dose q.d vs similar drugs
Pricing: SYL18001 sodium Middle dose q.d cost, discount & access